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Abstract
Background: For the pharmacological treatment of bipolar depression several guidelines exist. It is largely
unknown, to what extent the prescriptions in daily clinical routine correspond to these evidence based
recommendations and which combinations of psychotropic drugs are frequently used.
Methods: The prescriptions of psychotropic drugs were investigated of all in-patients with bipolar depression
(n = 2246; time period 1994–2009) from hospitals participating in the drug surveillance program AMSP. For the drug
use in 2010, 221 cases were analysed additionally.
Results: From 1994 to 2009, 85% of all patients received more than one class of psychotropic substances: 74%
received antidepressants in combination therapy, 55% antipsychotics, 48% anticonvulsants and 33% lithium. When
given in combination, lithium is the most often prescribed substance for bipolar depression (33%), followed by
valproic acid (23%), mirtazapine and venlafaxine (16% each), quetiapine (15%), lamotrigine (14%) and olanzapine
(13%). Both, lithium and valproic acid are often combined with selective serotonin reuptake inhibitors (SSRI), but
also with mirtazapine und venlafaxine. Combinations of more than one antidepressant occur quite often, whereby
combinations with bupropion, paroxetine, fluoxetine or fluvoxamine are very rare. In 2010, quetiapine (alone and
combined) was the most frequently prescribed drug (39%); aripiprazole was administered in 10%.
Conclusion: Combinations of antidepressants (SSRI, mirtazapine, venlafaxine) with mood stabilizers (lithium, valproic
acid, lamotrigine) and / or atypical antipsychotics (quetiapine, olanzapine) are common. Of most of those
combinations the efficacy has not been studied. The use of aripiprazole and the concomitant use of two or three
antidepressants contrast the guidelines.
Keywords: AMSP, Bipolar depression, Bipolar disorder, Combination therapy, Drug surveillance, Guidelines,
Pharmacotherapy, Prescription, Psychotropic drugs, Antidepressants
Background
For the treatment of bipolar depression a variety of
partly controversial options exist. Several up to date
guidelines provide clinicians with a framework of evi-
dence based pharmacological treatments of bipolar de-
pression [1-6].
The present study shows the prescriptions of psycho-
pharmacological substances for bipolar depression in
daily clinical routine. The data from a large European
multicenter study (AMSP) [7,8] allow a direct compari-
son between clinical routine and recommendations of
the guidelines.
Previous analysis of these data have shown several im-
portant prescribing trends in the treatment of bipolar
depression from 1994 until 2009: Antidepressants are
prescribed in almost 80% of all in-patients, thus being by
far the most important class of psychotropic drugs
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prescribed for bipolar depression; antipsychotics in
about 60% with increasing trend, especially for quetia-
pine; anticonvulsants in about 50%, mostly valproic acid
and lamotrigine and lithium in about 35% with a de-
creasing trend. Furthermore, a pronounced increase of
polypharmacy was found [9].
For the first time, the present article investigates spe-
cifically the most frequently administered combinations
of psychotropic substances and focuses on the use of
single antidepressant drugs over the time of 15 years in
hospitalized patients with bipolar depression.
Method
Patients
All in-patients with a diagnosis of bipolar depression hos-
pitalized in the participating hospitals of the AMSP pro-
ject were selected (n= 2246; time period 1994–2009). For
the years 2001 – 2009 patients with the diagnoses F 31.3 –
31.5 according to ICD 10 were selected, for the years
1994 – 2000 patients with the corresponding diagnosis in
ICD 9 (manic-depressive psychosis, circular type, currently
depressed) were included. A detailed description of the pa-
tient population can be found in Greil et al. 2012 [9]. For
the present analysis 15 patients with missing personal data
not included in the previous analysis were added to the
population. For the special calculation of drug use in 2010
additional 221 cases were analysed.
Data collection
The present data were taken from the large data pool of
the AMSP program (Arzneimittelsicherheit in der
Psychiatrie) [7]. This drug safety project was started in
1993 by the Psychiatric University Hospital Munich and
serves to continuously record prescriptions of psycho-
tropic drugs and their adverse side effects of in-patients
of various hospitals in Germany, Switzerland and Austria
(and temporarily also Hungary and Belgium). In 2009,
51 hospitals participated in the project. The data on pre-
scription rates were gathered twice a year as follows: At
two index dates per year each participating hospital /
ward recorded for each patient hospitalized at that day
age, sex, psychiatric diagnosis (ICD 9 and 10, respect-
ively) and daily dosage of all drugs (psychotropic and
non-psychotropic). These data were subsequently sent to
the Psychiatric University Hospital Munich, where they
were collected in an overall database.
Data analysis
To statistically analyse the rates of psychopharmacological
prescriptions, the percentage of patients per year was calcu-
lated, which received a particular agent. The number of
patients receiving a particular agent in one year was divided
by the total number of patients in this year =prescription
rate, i.e. percentage of patients receiving the agent per year.
Although the data were collected twice per calendar
year, an average prescription rate was calculated using
the data of one calendar year. Hence, we phrase “%
of patients” referring to virtual single patients. For
the analyses, the period 1994–2009 was segmented
into four equal time periods due to low number of
patients with single drugs.
The ethics committee of the Ludwig Maximilian Univer-
sity of Munich, the location of the AMSP main data cen-
ter, had approved the analysis of the AMSP data with a
waver of authorization. The permission to use the special
data set of bipolar depression was given by the publication
commission consisting of the presidents of the AMSP
associations in Germany, Austria and Switzerland.
Results
Frequency of prescriptions of drug classes in combination
therapy
Table 1 shows that within the period from 1994 to 2009,
85% of all hospitalized patients treated for bipolar
Table 1 Frequency of prescriptions in mono- and combination therapy for classes of psychotropic substances
1994 - 1997 1998 - 2001 2002 - 2005 2006 - 2009 Overall
N % N % N % N % N %
Number of patients 248 454 711 832 2246
Number of patients monotherapy 53 21.4 99 21.8 85 12.0 97 11.7 334 14.9
Number of patients combination therapy 195 78.6 355 78.2 626 88.0 735 88.3 1912 85.1
Antidepressants monotherapy 33 13.3 54 11.9 41 5.8 43 5.2 171 7.6
combination therapy 172 69.4 317 69.8 531 74.7 634 76.2 1655 73.7
Antipsychotics monotherapy 8 3.2 16 3.5 16 2.3 30 3.6 70 3.1
combination therapy 97 39.1 194 42.7 418 58.8 534 64.2 1244 55.4
Anticonvulsants monotherapy 6 2.4 16 3.5 15 2.1 14 1.7 51 2.3
combination therapy 65 26.2 177 39.0 402 56.5 425 51.1 1069 47.6
Lithium monotherapy 6 2.4 13 2.9 13 1.8 10 1.2 42 1.9
combination therapy 105 42.3 152 33.5 204 28.7 275 33.1 736 32.8
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depression received more than one class of psychotropic
substances: 74% of all patients received antidepressants,
55% antipsychotics, 48% anticonvulsants and 33% lith-
ium in combination therapy, i.e. in combination with
other drugs of these four drug classes.
Monotherapy had a low prevalence (about 15% of the
patients) and shows a decreasing trend. A remarkable
decrease is seen for antidepressant monotherapy, from
13% to 5% in the time period from 1994 to 1997 as com-
pared to the last period from 2006 to 2009. Hereby,
monotherapy is defined as the use of either antidepres-
sants or antipsychotics or anticonvulsants or lithium,
but additional use of hypnotics and tranquilizers or the
use of more than one drug within the respective class
being allowed (see also [9]).
Psychotropic substances in mono- and combination
therapy
Table 2 shows the single psychotropic substances pre-
scribed most frequently in mono- as well as in
combination therapy. When given in combination, lith-
ium is the most often prescribed substance for bipolar
depression (33%), followed by valproic acid (23%), mirta-
zapine and venlafaxine (16% each), quetiapine (15%),
lamotrigine (14%) and olanzapine (13%). The group of
SSRI is frequently included in combination therapy (26%
of the patients), especially escitalopram (9%) and citalo-
pram (8%). Note that paroxetine and fluoxetine are pre-
scribed rarely and fluvoxamine as well as bupropion are
given only exceptionally. Interestingly, quetiapine and
lamotrigine were often administered as combination
therapy, but very rarely as monotherapy (0.6% and 0.3%,
respectively).
The analysis of the prescription data from 2010
(patients with bipolar depression, n = 221) shows the fol-
lowing results for the most often used single drugs:
Quetiapine (alone and in combination) is prescribed in
38.9% of the patients, followed by valproic acid (33.5%),
lithium (26.7%), escitalopram (19.5%), lamotrigine
(18.6%), venlafaxine (17.7%) and mirtazapine (14.5%).
Table 2 Frequency of prescriptions of single psychotropic substances
% 1994 - 1997 1998 – 2001 2002 – 2005 2006 - 2009 Overall
N 248 454 711 832 2246
Lithium 2.4 + 42.3 2.9 + 33.5 1.8 + 28.7 1.2 + 33.1 1.9 + 32.8
SSRI overall 2.4 + 15.3 3.5 + 22.4 2.4 + 29 2.0 + 28.6 2.5 + 26.0
Valproic acid 0.4 + 4.8 1.8 + 19.8 1.5 + 28.4 1.3 + 24.4 1.4 + 22.8
Mirtazapine 3.2 2.6 + 12.1 2.1 + 20.7 2.0 + 18.8 2.0 + 16.3
Venlafaxine 2.0 + 4.4 1.1 + 10.4 1.3 + 21.5 1.1 + 18.3 1.2 + 16.2
Quetiapine 0.7 0.3 + 12.7 1.4 + 28.1 0.6 + 14.6
Lamotrigine 0.7 + 2.9 0.1 + 17.7 0.4 + 22.2 0.3 + 14.4
Olanzapine 0.4 0.9 + 9.5 0.7 + 18 1.1 + 13.6 0.8 + 12.7
Carbamazepine 2.0 + 21 1.8 + 18.7 0.4 + 10.4 0.2 + 5.5 0.8 + 11.4
Escitalopram 0.7 + 10.1 1.1 + 14.4 0.6 + 8.5
Citalopram 0.8 + 4.8 1.3 + 8.1 0.8 + 9.8 0.2 + 7 0.7 + 7.9
Risperidone 1.6 0.2 + 5.9 0.1 + 7.3 0.2 + 7.6 0.2 + 6.5
Sertraline 0.4 0.9 + 6.4 0.4 + 5.1 0.5 + 4.0 0.5 + 4.4
Paroxetine 0.8 + 8.5 1.3 + 5.3 0.1 + 2.5 2.4 0.4 + 3.7
Perazine 0.8 + 5.6 0.4 + 5.3 3.1 1.3 0.2 + 3.2
Reboxetine 1.1 + 2.9 0.1 + 4.2 0.2 + 3.0 0.4 + 3.0
Haloperidol 0.8 + 11.3 0.4 + 4.0 1.5 0.7 + 1.3 0.4 + 3.0
Duloxetine 0.1 + 1.5 0.1 + 6.6 0.1 + 2.9
Melperone 2.0 0.2 + 3.3 0.4 + 3.7 2.4 0.2 + 2.9
Promethazine 0.8 + 5.6 0.2 + 3.1 0.1 + 1.4 0.5 + 1.7 0.4 + 2.3
Aripiprazole 1.5 0.1 + 4.7 2.0
Clozapine 3.2 0.2 + 2.2 0.3 + 1.7 0.1 + 1.8 0.2 + 2.0
Fluoxetine 0.8 + 1.6 2.6 0.4 + 1.5 0.2 + 0.8 0.3 + 1.5
Table 2: Monotherapy (small numbers) and combination therapy (fat numbers) in percent (%) of all patients per time period. The substances are listed according
to their frequency of prescription, with the most often prescribed substance listed first. Substances with overall prescription rates below 1.5% are not presented.
Year of licensing in the respective countries: lamotrigine: epilepsy 1994, long term bipolar depression 2003; olanzapine: schizophrenia 1996, long term mania
2003; quetiapine: schizophrenia 2000, mania 2004, bipolar depression 2009.
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Interestingly, aripiprazole (10.0%) is prescribed more
often than olanzapine (9.1%). The group of SSRI is pre-
scribed in 30.9%.
Frequent combinations of psychotropic substances
Table 3 a and b gives the most frequent combinations of
at least two or three psychotropic substances in the time
period from 1994 to 2009. The results show, that fre-
quent combinations include lithium, SSRI, mirtazapine,
venlafaxine, valproic acid, lamotrigine, quetiapine and
olanzapine. Both, lithium and valproic acid are often
combined with SSRI, but also with mirtazapine and ven-
lafaxine. Particular combinations with risperidone are
not frequent (< 3%) and hence not included in the table.
Combinations with bupropion, fluoxetine, fluvoxamine
or paroxetine are very rare and therefore not presented.
Frequent combinations of classes of substances
Table 4 shows a summary of the most frequent combi-
nations of classes of psychotropic drugs in the treatment
of bipolar depression. Most combinations include anti-
depressants, mainly SSRI. Interestingly, also combi-
nations of two and more antidepressant drugs occur,
e.g. SSRI plus mirtazapine plus venlafaxine.
Discussion
The present study focuses on the psychopharmacological
combination treatment of bipolar depression in hospita-
lized patients in the time period 1994–2009. It shows
that lithium given in about one third of the patients is
the most frequently administered single substance given
at all and concomitantly with other psychotropic drugs.
This is also found for the time period 2006–2009, even
though the trend to prescribe lithium has decreased over
the last 15 years [9]. The data, however, do not allow a
specification whether lithium is given due to its anti-
depressant property, as an augmentation strategy or for
preventive purpose.
Clinical studies on the efficacy of lithium show a mod-
est antidepressant effect of lithium in bipolar depression,
at best [10-13]. Nevertheless, several guidelines include
lithium as a fist-line treatment option alone [4,6] or in
combination with other substances, e.g. lamotrigine [2].
The combinations of lithium with other psychotropic
drugs found in the present data only include substances
that do not interfere with the pharmacokinetics of lith-
ium. Only the risk of serotonergic syndrome may be
increased in combinations of lithium with SSRI and / or
venlafaxine.
Table 3 a and b Most frequent combinations of at least
two and three substances
a.
Lithium SSRI 9.2%
Valproic acid SSRI 7.2
Lithium Mirtazapine 5.8
Lithium Venlafaxine 5.7
Quetiapine SSRI 5.2
Quetiapine Lithium 5.1
Lamotrigine SSRI 4.9
Valproic acid Venlafaxine 4.6
Valproic acid Mirtazapine 4.5
Valproic acid Lithium 4.1
Quetiapine Lamotrigine 3.9
SSRI Mirtazapine 3.8
Olanzapine Lithium 3.7
Lamotrigine Venlafaxine 3.7
Olanzapine SSRI 3.6
Quetiapine Valproic acid 3.4
Mirtazapine Venlafaxine 3.4
Lamotrigine Lithium 3.3
Valproic acid Olanzapine 3.2
Lamotrigine Mirtazapine 3.2
b.
SSRI Quetiapine Lithium 1.7%
SSRI Quetiapine Lamotrigine 1.3
SSRI Mirtazapine Lithium 1.2
SSRI Mirtazapine Valproic acid 1.2
SSRI Mirtazapine Venlafaxine 1.2
Lithium Mirtazapine Venlafaxine 1.2
SSRI Olanzapine Lithium 1.1
Lithium Quetiapine Venlafaxine 1.1
Lithium Quetiapine Lamotrigine 1.1
Table 3a and b: Most frequent combinations (> 3% and> 1%, respectively) of
at least two substances (Table 3a) and three substances (Table 3b) in percent
(%) of all patients with bipolar depression (1994–2009).
Table 4 Most frequent combinations of classes of
psychotropic drugs
Lithium Antidepressants
(SSRI, Mir, Ven)
atypical Neuroleptics
(Quet, Ola, Ri)
4%
Lithium Antidepressants
(SSRI, Mir, Ven)
Antidepressants
(SSRI, Mir, Ven)
3%
Lithium atypical Neuroleptics
(Quet, Ola, Ri)
Anticonvulsives
(Val, Lam)
1%
SSRI atypical Neuroleptics
(Quet, Ola, Ri)
Anticonvulsives
(Val, Lam)
3%
SSRI Mirtazapine Anticonvulsives
(Val, Lam)
2%
SSRI Mirtazapine Venlafaxine 1%
Table: 4 Classes of psychotropic drugs in the treatment of bipolar depression
(1994–2009). Mir: mirtazapine, Ven: venlafaxine, Quet: quetiapine, Ola:
olanzapine, Ri: risperidone, Val: valproic acid, Lam: lamotrigine.
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The data also emphasize, that antidepressants are the
most frequently prescribed class of drugs given in com-
bination, although the use of antidepressants in bipolar
depression is controversial. Since 2002, in US guidelines
it is generally recommended to avoid antidepressants in
bipolar depression [14]. Especially for mirtazapine and
venlafaxine, both found in the present study to be com-
bined often with lithium and valproic acid respectively,
there is no data that supports the efficacy of these
combinations.
In 2002, international [15] and US guidelines [14] pro-
posed the combination of a non-tricyclic antidepressant
(SSRI or bupropion) with mood stabilizer (lithium or
lamotrigine) as a treatment option. In accordance with
these recommendations and with modern guidelines,
that in bipolar depression antidepressants should be pre-
scribed in combination with mood stabilizing and anti-
manic drugs only we observed that antidepressants are
combined mainly with lithium, valproic acid, quetiapine
and lamotrigine. However, the evidence based combin-
ation recommended by the guidelines, olanzapine plus
fluoxetine (OFC), was found to be prescribed only in
very few patients (cf. [9]). Bupropion, listed in inter-
national guidelines as an antidepressant specifically
recommended for bipolar depression, is administered
very rarely. Moreover, antidepressants with a high poten-
tial for pharmacokinetic interactions, i.e. paroxetine, flu-
oxetine and fluvoxamine, are not used within the usual
combinations. Hence, critical drug-drug interactions are
avoided despite increasing polypharmacy (cf. [16]). A
trend to polypharmacy has already been described in the
treatment of bipolar disorder generally [17-19], a sys-
tematic description of this trend for the treatment of bi-
polar depression is - to our knowledge - given for the
first time in our previous [9] and present analysis.
Within the time period of 2006 – 2009, the anticon-
vulsants valproic acid and lamotrigine were the third
and fourth most frequently given substances for bipolar
depression and more than every fifth patient receives
valproic acid or lamotrigine in combination with other
drugs. The efficacy of valproic acid has been validated in
clinical studies and recent meta-analyses [20], whereby
the efficacy of lamotrigine is still a controversial issue
and only a modest antidepressant effect can be expected
[21]. In 2004, an international consensus group on Bipo-
lar I Depression Treatment Guidelines recommended
lamotrigine with category 1 evidence [22].
Quetiapine was found in the present study to be the
second most frequently prescribed substance for bipolar
depression during the period from 2006 to 2009,
whereby the number of prescriptions has increased rap-
idly in the last ten years [9]. In 2010, quetiapine was
even the most often prescribed single substance, fol-
lowed by valproic acid and lithium. Evidence for the
efficacy of quetiapine in the treatment of bipolar depres-
sion is ample [13,23-26]. Therefore, all international
guidelines explicitly recommend quetiapine as first line
treatment, usually proposed as monotherapy [1-6].
Already in 2005, in the Texas algorithms for treatment
of bipolar I depression quetiapine was proposed besides
lamotrigine and olanzapine / fluoxetine combination
[27] and in 2007, quetiapine was recommended as first
line treatment option by the international CANMAT
guidelines [28]. However, monotherapy of quetiapine is
very unusual in our data and quetiapine was found to be
combined frequently with SSRI and mood stabilizers
(lithium, valproic acid or lamotrigine). Note that aripi-
prazole was prescribed in 2010 in 10% of the patients
despite negative trials for bipolar depression [6].
The present study bears some limitations, a detailed
description of which is given in Greil et al. 2012 [9].
Most importantly, the study is based on data from hos-
pitalized patients, which suffer from severe depression
usually and may be treatment resistant as well. Thus,
this population may need a higher number of psycho-
tropic drugs concomitantly as compared to out-patients.
Moreover, polypharmacy in our population may be over-
estimated due to tapering off ineffective drugs and start-
ing new medications.
Overall, the study shows, that multiple combinations
of psychotropic substances for therapy of bipolar depres-
sion are daily clinical routine. Combinations of antide-
pressants (SSRI, mirtazapine, venlafaxine) with mood
stabilizers (lithium, valproic acid, lamotrigine) and/or
atypical neuroleptics (quetiapine, olanzapine, risperi-
done) are common and combinations of more than one
antidepressant substance occur quite often.
The efficacy of these frequent combinations applied
has not yet been investigated thoroughly. There is a gen-
eral agreement, that mood stabilizers (lithium, valpoic
acid, lamotrigine) combined with atypical neuroleptics
may be efficacious in acute bipolar depression [29-32].
In contrast, the efficacy of combinations with antide-
pressants, especially with mirtazapine and venlafaxine
and the efficacy of combinations involving multiple anti-
depressant substances are not supported by research
data. No studies on the efficacy of mirtazapine for bipo-
lar disorder exist. Concerning venlafaxine, its efficacy in
the treatment of bipolar II depression has been shown in
small sample sizes only [33-35] and one study shows
that venlafaxine may trigger switches to mania [36]. Re-
cent reviews and studies on the efficacy of antidepres-
sants alone or in combination in the treatment of
bipolar depression do not find stable effects for their ef-
ficacy [37-42]. Indicating awareness of drug safety, com-
binations with substances that have high interaction
properties such as paroxetine, fluoxetine and fluvox-
amine were found to be scarce in our data.
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Conclusion
The present study shows that administration of combi-
nations of psychotropic drugs is an every day
phenomenon in clinical routine, although profound
knowledge about their efficacy is missing. Corresponding
recommendations in international guidelines based on
clinical trials on the treatment of bipolar depression
would constitute great assistance for physicians, but they
are not yet available.
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